Retrospective study of 81 patients treated with brachytherapy for endobronchial primary tumor or metastasis
Received 11 June 2009; received in revised form 29 October 2009; accepted 23 November 2009. published online 01 February 2010.
Abstract
Purpose
The purpose of this retrospective study is to evaluate the role of endobronchial brachytherapy in the palliation of lung cancer (or metastasis) symptoms and its potential impact on overall survival.
Methods and Materials
Eighty-one patients were included in this study. Endobronchial brachytherapy catheter was placed under conscious sedation. The projection of the tumor was drawn by the bronchoscopist to help the radiation oncology team to perform the dosimetry. Patients were treated with iridium-192 high-dose rate afterloading unit. Patients were planned to receive 5Gy in four fractions weekly for a total of 20Gy.
Results
Seventy-three percent of the patients were treated for primary lung cancer. The remaining patients were treated for lung metastasis of other primary. Most patients presented dyspnea, cough, or hemoptysis. These three main symptoms were relieved in 85%, 77%, and 100%, respectively. The median survival was 14.7 months and local progression-free survival at 12 months was 77% and at 24 months 64%, respectively.
Conclusion
Endobronchial brachytherapy is a very effective palliative treatment for endobronchial lesions.
ABSTRACT